Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR444245 combinations in advanced gastrointestinal cancers
NL-OMON52360Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegenzileukin in gastrointestinal cancer, Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC) and 1 more (4 arms), sponsored by Sanofi. Primary endpoint: Objective response rate. Started May 2022; status: active, not recruiting.
02
Drugs
pegenzileukin
03
Conditions
gastrointestinal cancerEsophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON52360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52360.